{"id":786468,"date":"2023-09-27T11:30:05","date_gmt":"2023-09-27T15:30:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/"},"modified":"2023-09-27T11:30:05","modified_gmt":"2023-09-27T15:30:05","slug":"virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/","title":{"rendered":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies"},"content":{"rendered":"

<\/p>\n

Virpax Pharmaceuticals Announces Results of Probudur\u2122<\/sup> Dose Escalation Studies<\/b><\/p>\n

BERWYN, Pa.–(BUSINESS WIRE<\/a>)–Virpax\u00ae<\/sup> Pharmaceuticals, Inc.<\/a> (\u201cVirpax\u201d or the \u201cCompany\u201d) (NASDAQ: VRPX),<\/b> a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for two pre-clinical Probudur\u2122 dose escalation studies.<\/p>\n

\nThe first study compared Probudur to Exparel\u00ae<\/sup> utilizing a planar incision model. Two doses of Probudur, at 3 mg and 6 mg, were administered to rats. The results demonstrated three times longer efficacy for Probudur than Exparel.<\/p>\n

\nIn the second study, two different formulations at the same dose of Probudur were compared to Exparel in rat incision models. In this study, Probudur demonstrated a four to five times longer effect than the comparable product.<\/p>\n

\n\u201cThese IND enabling studies confirmed our results from earlier studies,\u201d commented Anthony P. Mack<\/a>, Chairman and CEO of Virpax Pharmaceuticals. \u201cWe only have a few additional studies to be performed and are on track to begin first-in-human trials of Probudur in 2024.\u201d<\/p>\n

\nAdditional confirmational studies for efficacy, toxicity, and pharmacokinetics are ongoing with others planned in order for the Company to file an Investigational New Drug (IND) Application.<\/p>\n

About Virpax Pharmaceuticals<\/b><\/p>\n

\nVirpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur\u2122<\/a> is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta\u2122<\/a> is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET)<\/a> to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol\u2122<\/a> is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax has competitive cooperative research and development agreements (CRADAs) for all three of its prescription drug candidates, two with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm\u2122, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com<\/a> and follow us on Twitter<\/a>, LinkedIn<\/a> and YouTube<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and Private Securities Litigation Reform Act, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.<\/p>\n

\nThese statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,\u201d “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms and include statements regarding the Company\u2019s anticipated studies for efficacy, toxicity and pharmacokinetics, the Company\u2019s filing of an IND Application, and the Company\u2019s anticipated first-in-human trials of Probudur\u2122<\/sup> in 2024. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the Company\u2019s ability to successfully complete research and further development and commercialization of Company drug candidates in current or future indications; the uncertainties inherent in clinical testing; the Company\u2019s ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals for the Company\u2019s product candidates; the Company\u2019s ability to protect its intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s product candidates; the Company\u2019s ability to continue to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete clinical trials that the Company plans to initiate; and other factors listed under “Risk Factors” in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230927781607\/en\/<\/a><\/span><\/p>\n

Investor Relations:
\n<\/span><\/b>
Betsy Brod
\n
Affinity Growth Advisors
\n
Betsy.brod@affinitygrowth.com
\n<\/a>
(917) 923-8541<\/p>\n

Media:
\n<\/span><\/b>
Robert Cavosi
\n
RooneyPartners
\n
rcavosi@rooneypartners.com
\n<\/a>
(646) 638-9891<\/p>\n

KEYWORDS:<\/b> Pennsylvania New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Other Health Finance Practice Management Pharmaceutical Surgery Professional Services Medical Devices Infectious Diseases Hospitals Clinical Trials Biotechnology Science Veterinary Other Science Research Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies BERWYN, Pa.–(BUSINESS WIRE)–Virpax\u00ae Pharmaceuticals, Inc. (\u201cVirpax\u201d or the \u201cCompany\u201d) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for two pre-clinical Probudur\u2122 dose escalation studies. The first study compared Probudur to Exparel\u00ae utilizing a planar incision model. Two doses of Probudur, at 3 mg and 6 mg, were administered to rats. The results demonstrated three times longer efficacy for Probudur than Exparel. In the second study, two different formulations at the same dose of Probudur were compared to Exparel in rat incision models. In this study, Probudur demonstrated a four to five times … <\/p>\n

Continue reading “Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVirpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies BERWYN, Pa.–(BUSINESS WIRE)–Virpax\u00ae Pharmaceuticals, Inc. (\u201cVirpax\u201d or the \u201cCompany\u201d) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for two pre-clinical Probudur\u2122 dose escalation studies. The first study compared Probudur to Exparel\u00ae utilizing a planar incision model. Two doses of Probudur, at 3 mg and 6 mg, were administered to rats. The results demonstrated three times longer efficacy for Probudur than Exparel. In the second study, two different formulations at the same dose of Probudur were compared to Exparel in rat incision models. In this study, Probudur demonstrated a four to five times … Continue reading "Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T15:30:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies\",\"datePublished\":\"2023-09-27T15:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/\"},\"wordCount\":879,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/\",\"name\":\"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-09-27T15:30:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/","og_locale":"en_US","og_type":"article","og_title":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk","og_description":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies BERWYN, Pa.–(BUSINESS WIRE)–Virpax\u00ae Pharmaceuticals, Inc. (\u201cVirpax\u201d or the \u201cCompany\u201d) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for two pre-clinical Probudur\u2122 dose escalation studies. The first study compared Probudur to Exparel\u00ae utilizing a planar incision model. Two doses of Probudur, at 3 mg and 6 mg, were administered to rats. The results demonstrated three times longer efficacy for Probudur than Exparel. In the second study, two different formulations at the same dose of Probudur were compared to Exparel in rat incision models. In this study, Probudur demonstrated a four to five times … Continue reading \"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-27T15:30:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies","datePublished":"2023-09-27T15:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/"},"wordCount":879,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/","name":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-09-27T15:30:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230927781607r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virpax-pharmaceuticals-announces-results-of-probudur-dose-escalation-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}